RPRoy William Peake

Roy William Peake

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Roy William Peake has a total of 59 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Application of high-resolution mass spectrometry profiling towards the diagnosis and acute management of maple syrup urine disease

    by Rafael Garrett, Sara Pickett, Melinda J. Peters, Khadija Belhassan, Adam S. Ptolemy, Roy W.A. Peake


  • Untargeted Metabolomics for Inborn Errors of Metabolism: Development and Evaluation of a Sustainable Reference Material for Correcting Inter-Batch Variability

    by Rafael Garrett, Adam S Ptolemy, Sara Pickett, Mark D Kellogg, Roy W A Peake

    Untargeted metabolomics has shown promise in expanding screening and diagnostic capabilities for inborn errors of metabolism (IEMs). However, inter-batch variability remains a major barrier to its implementation in the clinical laboratory, despite attempts to address this through normalization techniques. We have developed a sustainable, matrix-matched reference material (RM) using the iterative batch averaging method (IBAT) to correct inter-batch variability in liquid chromatography-high-resolution mass spectrometry-based untargeted metabolomics for IEM screening. The RM was created using pooled batches of remnant plasma specimens. The batch size, number of batch iterations per RM, and stability compared to a conventional pool of specimens were determined. The effectiveness of the RM for correcting inter-batch variability in routine screening was evaluated using plasma collected from a cohort of phenylketonuria (PKU) patients. The RM exhibited lower metabolite variability between iterations over time compared to metabolites from individual batches or individual specimens used for its creation. In addition, the mean variation across amino acid (n = 19) concentrations over 12 weeks was lower for the RM (CVtotal = 8.8%; range 4.7%–25.3%) compared to the specimen pool (CVtotal = 24.6%; range 9.0%–108.3%). When utilized in IEM screening, RM normalization minimized unwanted inter-batch variation and enabled the correct classification of 30 PKU patients analyzed 1 month apart from 146 non-PKU controls. Our RM minimizes inter-batch variability in untargeted metabolomics and demonstrated its potential for routine IEM screening in a cohort of PKU patients. It provides a practical and sustainable solution for data normalization in untargeted metabolomics for clinical laboratories.


  • Open Access

    Author Correction: Clinical Validation of Targeted and Untargeted Metabolomics Testing for Genetic Disorders: A 3 Year Comparative Study

    by Naif A. M. Almontashiri, Li Zha, Kim Young, Terence Law, Mark D. Kellogg, Olaf A. Bodamer, Roy W. A. Peake

    An amendment to this paper has been published and can be accessed via a link at the top of the paper.


  • Open Access

    Clinical Validation of Targeted and Untargeted Metabolomics Testing for Genetic Disorders: A 3 Year Comparative Study

    by Naif A. M. Almontashiri, Li Zha, Kim Young, Terence Law, Mark D. Kellogg, Olaf A. Bodamer, Roy W. A. Peake

    Global untargeted metabolomics (GUM) has entered clinical diagnostics for genetic disorders. We compared the clinical utility of GUM with traditional targeted metabolomics (TM) as a screening tool in patients with established genetic disorders and determined the scope of GUM as a discovery tool in patients with no diagnosis under investigation. We compared TM and GUM data in 226 patients. The first cohort (n = 87) included patients with confirmed inborn errors of metabolism (IEM) and genetic syndromes; the second cohort (n = 139) included patients without diagnosis who were undergoing evaluation for a genetic disorder. In patients with known disorders (n = 87), GUM performed with a sensitivity of 86% (95% CI: 78–91) compared with TM for the detection of 51 diagnostic metabolites. The diagnostic yield of GUM in patients under evaluation with no established diagnosis (n = 139) was 0.7%. GUM successfully detected the majority of diagnostic compounds associated with known IEMs. The diagnostic yield of both targeted and untargeted metabolomics studies is low when assessing patients with non-specific, neurological phenotypes. GUM shows promise as a validation tool for variants of unknown significance in candidate genes in patients with non-specific phenotypes.


  • Abnormal Glycerol Metabolism in a Child with Global Developmental Delay, Adrenal Insufficiency, and Intellectual Disability

    by Naif A.M. Almontashiri, Gerard T. Berry, Joseph Majzoub, Roy W A Peake

    After an uncomplicated birth and initial symptom-free period, a 7-day-old male infant presented with poor feeding, hypotension, hyponatremia (123 mmol/L; reference interval, 135–148), hyperkalemia (9.0 mmol/L; reference interval, 3.5–5.5), and increased blood urea nitrogen. A diagnosis of primary adrenal insufficiency was made following an adrenal ultrasound remarkable for no discernable adrenal tissue. Subsequent fluorescent in situ hybridization studies revealed deletions in the region containing the NR0B1 ,5 IL1RAPL1 , and GK genes in both the patient (for which he was treated with adrenocorticosteroids) and his asymptomatic mother. At approximately 4 years of age, he experienced a hypoglycemic episode (plasma glucose, 42 mg/dL). Fasting triglyceride level was also increased at 465 mg/dL (reference interval, <250). Approximately 1 year later, he presented again to the emergency room with vomiting, headaches, lethargy, cramps, and diarrhea. Clinical examination showed a developmentally delayed child with hypotonia and strabismus. He had iatrogenic Cushing syndrome. There was evidence of microorchidism, meatal stenosis, congenital hydroceles, and bilateral inguinal hernia. As part of follow-up studies, an array comparative genomic hybridization was performed. A urine specimen was also collected for organic acid analysis using GC-MS (Fig. 1). Fig. 1. Organic acid analysis of patient urine using GC-MS. Urine organic acids were extracted into ethyl acetate/ether and converted to trimethylsilyl derivatives before analysis using a GC 6890N/MS 5975 system equipped …


  • Open Access

    Arginine does not rescue p.Q188R mutation deleterious effect in classic galactosemia

    by Minela Haskovic, Britt Derks, Liesbeth van der Ploeg, Jorn Trommelen, Jean Nyakayiru, Luc J. C. van Loon, Sabrina Mackinnon, Wyatt W. Yue, Roy W. A. Peake, Li Zha, et al.

    Classic galactosemia is a rare genetic metabolic disease with an unmet treatment need. Current standard of care fails to prevent chronically-debilitating brain and gonadal complications. Many mutations in the GALT gene responsible for classic galactosemia have been described to give rise to variants with conformational abnormalities. This pathogenic mechanism is highly amenable to a therapeutic strategy based on chemical/pharmacological chaperones. Arginine, a chemical chaperone, has shown beneficial effect in other inherited metabolic disorders, as well as in a prokaryotic model of classic galactosemia. The p.Q188R mutation presents a high prevalence in the Caucasian population, making it a very clinically relevant mutation. This mutation gives rise to a protein with lower conformational stability and lower catalytic activity. The aim of this study is to assess the potential therapeutic role of arginine for this mutation. Arginine aspartate administration to four patients with the p.Q188R/p.Q188R mutation, in vitro studies with three fibroblast cell lines derived from classic galactosemia patients as well as recombinant protein experiments were used to evaluate the effect of arginine in galactose metabolism. This study has been registered at https://clinicaltrials.gov (NCT03580122) on 09 July 2018. Retrospectively registered. Following a month of arginine administration, patients did not show a significant improvement of whole-body galactose oxidative capacity (p = 0.22), erythrocyte GALT activity (p = 0.87), urinary galactose (p = 0.52) and urinary galactitol levels (p = 0.41). Patients’ fibroblasts exposed to arginine did not show changes in GALT activity. Thermal shift analysis of recombinant p.Q188R GALT protein in the presence of arginine did not exhibit a positive effect. This short pilot study in four patients homozygous for the p.Q188R/p.Q188R mutation reveals that arginine has no potential therapeutic role for galactosemia patients homozygous for the p.Q188R mutation.


  • Commentary

    by Roy Peake

    For measurement of amino acids, the majority of laboratories use a version of amine derivatization in combination with column chromatography and absorbance-based detection (1, 2). The susceptibility of amine derivatization to interferences from the substantial number of drugs harboring amine functional groups has been the downside of this approach. Over the years, offending drugs were successfully catalogued, and the knowledge was shared among the laboratory community. This was possible because of the popularity of the ubiquitous Amino Acid Analyzer, as chromatographic profiles …


  • Hyperammonemia in a Child Presenting with Growth Delay, Short Stature, and Diarrhea

    by Naif A.M. Almontashiri, Didem Demirbas, Gerard T. Berry, Roy W A Peake

    A 5-year-old male child was referred to the metabolism clinic with a history of failure to thrive, chronic intermittent emesis, diarrhea, seizures, hypotonia, and growth hormone deficiency. He was also noted to experience frequent falling episodes. Routine biochemistry testing revealed increased plasma ammonia concentration at 184 μmol/L (reference interval, 16–47) and lactate dehydrogenase concentration at 445 U/L (reference interval, 110–295). Plasma free and total carnitine concentrations were decreased at 5 μmol/L (reference interval, 26–60) and 17.1 μmol/L (reference interval, 32–84), respectively. Orotic acid excretion in urine was also markedly increased at >80 mmol/mol creatinine (reference interval, 0.2–1.5). Plasma insulin-like growth factor-I (IGF-I)4 concentration was also decreased at <25 ng/mL (reference interval, 50–286). Paired plasma and urine specimens were collected for amino acid analysis using ultraperformance liquid chromatography. The results are shown in Table 1. View this table: Table 1. Amino acid analysis of paired plasma and urine. This patient has lysinuric protein intolerance (LPI), an autosomal recessive disorder of amino acid transport, caused by mutations in the solute carrier family 7, member 7 ( SLC7A7 ) gene (1, 2, 3). Although the worldwide incidence is not known, LPI is estimated to occur in approximately 1 in 60000 newborns in Finland and Japan (2). The SLC7A7 gene product is the …